GYRE Relative Valuation
GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GYRE is overvalued; if below, it's undervalued.
Historical Valuation
Gyre Therapeutics Inc (GYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 11.13. The fair price of Gyre Therapeutics Inc (GYRE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.56
Fair
36.74
PE
1Y
3Y
5Y
Trailing
Forward
38.90
EV/EBITDA
Gyre Therapeutics Inc. (GYRE) has a current EV/EBITDA of 38.90. The 5-year average EV/EBITDA is 8.21. The thresholds are as follows: Strongly Undervalued below -26.68, Undervalued between -26.68 and -9.23, Fairly Valued between 25.65 and -9.23, Overvalued between 25.65 and 43.10, and Strongly Overvalued above 43.10. The current Forward EV/EBITDA of 38.90 falls within the Overvalued range.
97.25
EV/EBIT
Gyre Therapeutics Inc. (GYRE) has a current EV/EBIT of 97.25. The 5-year average EV/EBIT is 15.09. The thresholds are as follows: Strongly Undervalued below -46.57, Undervalued between -46.57 and -15.74, Fairly Valued between 45.92 and -15.74, Overvalued between 45.92 and 76.75, and Strongly Overvalued above 76.75. The current Forward EV/EBIT of 97.25 falls within the Strongly Overvalued range.
4.68
PS
Gyre Therapeutics Inc. (GYRE) has a current PS of 4.68. The 5-year average PS is 1.30. The thresholds are as follows: Strongly Undervalued below -3.32, Undervalued between -3.32 and -1.01, Fairly Valued between 3.62 and -1.01, Overvalued between 3.62 and 5.93, and Strongly Overvalued above 5.93. The current Forward PS of 4.68 falls within the Overvalued range.
69.61
P/OCF
Gyre Therapeutics Inc. (GYRE) has a current P/OCF of 69.61. The 5-year average P/OCF is 10.60. The thresholds are as follows: Strongly Undervalued below -30.32, Undervalued between -30.32 and -9.86, Fairly Valued between 31.06 and -9.86, Overvalued between 31.06 and 51.52, and Strongly Overvalued above 51.52. The current Forward P/OCF of 69.61 falls within the Strongly Overvalued range.
35.16
P/FCF
Gyre Therapeutics Inc. (GYRE) has a current P/FCF of 35.16. The 5-year average P/FCF is 3.31. The thresholds are as follows: Strongly Undervalued below -17.76, Undervalued between -17.76 and -7.23, Fairly Valued between 13.84 and -7.23, Overvalued between 13.84 and 24.37, and Strongly Overvalued above 24.37. The current Forward P/FCF of 35.16 falls within the Strongly Overvalued range.
Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 6.81. Compared to its 3-year average P/B ratio of -5.83 , the current P/B ratio is approximately -216.80% higher. Relative to its 5-year average P/B ratio of -5.83, the current P/B ratio is about -216.80% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 0.03% , the current FCF yield is about -100.00% lower.
7.05
P/B
Median3y
-5.83
Median5y
-5.83
0.42
FCF Yield
Median3y
0.03
Median5y
0.03
Competitors Valuation Multiple
The average P/S ratio for GYRE's competitors is , providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 19.92%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GYRE decreased by 34.71% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 11.21 to 19.42.
The secondary factor is the Revenue Growth, contributed 19.92%to the performance.
Overall, the performance of GYRE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Gyre Therapeutics Inc (GYRE) currently overvalued or undervalued?
What is Gyre Therapeutics Inc (GYRE) fair value?
How does GYRE's valuation metrics compare to the industry average?
What is the current P/B ratio for Gyre Therapeutics Inc (GYRE) as of Dec 05 2025?
What is the current FCF Yield for Gyre Therapeutics Inc (GYRE) as of Dec 05 2025?
What is the current Forward P/E ratio for Gyre Therapeutics Inc (GYRE) as of Dec 05 2025?